Products
Lumiracoxib (Prexige, Joicela, film-coated tablets) is no longer on the market or has not been approved in many countries because of its liver-toxic properties. The drug was not registered in many countries.
Structure and properties
Lumiracoxib (C15H13ClFNO2, Mr = 293.7 g/mol) is an analog of diclofenac (Voltaren) and belongs to the phenylacetic acid derivatives. It is structurally distinct from other COX-2 inhibitors such as celecoxib.
Effects
Lumiracoxib (ATC M01AH06) has analgesic, anti-inflammatory, and antipyretic properties. The effects are due to highly selective inhibition of the enzyme cyclooxygenase-2 and the biosynthesis of prostaglandins. Lumiracoxib has a short half-life of four hours, but once-daily administration is sufficient.
Indications
- For the treatment of acute symptoms associated with knee osteoarthritis or hip osteoarthritis.
- Acute pain
- Menstrual pain
